{"name":"SCRI Development Innovations, LLC","slug":"scri-development-innovations-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CVP","genericName":"CVP","slug":"cvp","indication":"Chronic lymphocytic leukemia (CLL)","status":"marketed"},{"name":"BKM120 and Erlotinib","genericName":"BKM120 and Erlotinib","slug":"bkm120-and-erlotinib","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Ixabepilone (Ixempra)","genericName":"Ixabepilone (Ixempra)","slug":"ixabepilone-ixempra","indication":"Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Toremifine","genericName":"Toremifine","slug":"toremifine","indication":"Other","status":"phase_2"},{"name":"CAMPTH-1H","genericName":"CAMPTH-1H","slug":"campth-1h","indication":"Other","status":"phase_2"},{"name":"RAD001","genericName":"RAD001","slug":"rad001","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"BMS-986489","genericName":"BMS-986489","slug":"bms-986489","indication":"Treatment of systemic lupus erythematosus","status":"phase_2"}]}],"pipeline":[{"name":"CVP","genericName":"CVP","slug":"cvp","phase":"marketed","mechanism":"CVP is a chemotherapy regimen combining cyclophosphamide, vincristine, and prednisone to suppress cancer cell growth through multiple cytotoxic and immunosuppressive mechanisms.","indications":["Chronic lymphocytic leukemia (CLL)","Non-Hodgkin's lymphoma","Hodgkin's lymphoma"],"catalyst":""},{"name":"Toremifine","genericName":"Toremifine","slug":"toremifine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BKM120 and Erlotinib","genericName":"BKM120 and Erlotinib","slug":"bkm120-and-erlotinib","phase":"phase_2","mechanism":"BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR.","indications":["Non-small cell lung cancer","Pancreatic cancer"],"catalyst":""},{"name":"BMS-986489","genericName":"BMS-986489","slug":"bms-986489","phase":"phase_2","mechanism":"BMS-986489 is an anti-inflammatory agent.","indications":["Treatment of systemic lupus erythematosus"],"catalyst":""},{"name":"CAMPTH-1H","genericName":"CAMPTH-1H","slug":"campth-1h","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ixabepilone (Ixempra)","genericName":"Ixabepilone (Ixempra)","slug":"ixabepilone-ixempra","phase":"phase_3","mechanism":"Ixabepilone stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.","indications":["Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy)","Taxane-resistant breast cancer"],"catalyst":""},{"name":"RAD001","genericName":"RAD001","slug":"rad001","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONWltN0FMUVRwUXB2bUtnQ09tZVJNTGhQV3Zaam9BQi10NDA0OFk5Qmd1ZlJsX0VhdURpdjhuT0NqUGNEb1czV21FVWR5a2ZpWVhrSXVSbjVqSHRqOUJ3NG5MbHJhQlBmMV9XSTlBTDRROHdGMDlyVFZQclNzWkduUm92bTc1bGZCdXR4WVdnUXVzS0ZkMWpOdWZxQkZwWUlxT0g3NmNZazNXdGM?oc=5","date":"2025-05-28","type":"trial","source":"Fierce Biotech","summary":"AbbVie taps oncology research institute for aid running diverse cancer trials - Fierce Biotech","headline":"AbbVie taps oncology research institute for aid running diverse cancer trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOY2l5NUtMWkVOcnlxbE1FR2M2Rmlpc3NRTUhzOFQtWFVCcVFzV3RWdnktM0h0NUE2Tm9FWnotc1FjU212V2pQM003a2E3blVQaTltT3I0RHZwdEowV1d4R3dLZ1VCOXlWMnZsSE5HY1dzUm5oZlEzRmVhaG43TVBIRlFjN3JXZ2daQUd1SFBKeUpWMm5GRTJmYXdIRkdVc3Bj?oc=5","date":"2024-02-29","type":"trial","source":"Fierce Biotech","summary":"SCRI and AstraZeneca strike deal for cancer clinical trials solutions - Fierce Biotech","headline":"SCRI and AstraZeneca strike deal for cancer clinical trials solutions","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":2,"phase_2":4,"phase_3":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}